 
Document Type:  Study Protocol 
Official Title:  A non-blinded retrospective biomarker add-on study to 
FIGARO -DKD for B ioprofiling the phar Macodynamic response 
to finerenone in FIGARO- DKD subjects ( FIGARO -BM) 
Study ID: [REMOVED] 
Document Date:  24 JUN 2021 
 
 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 1of 25
Title Page
Protocol Title: 
A non-blinded retrospective biomarker add -on study to FIGARO -DKD for Bioprofiling the 
pharMacody namic response to finerenone in FIGARO -DKD subjects (FIGARO -BM)
Protocol Number: 21952
Version Number: 1.0
Compound Number: Finerenone (BAY 94-8862)
Study Phase: N/A
Acronym: FIGARO -BM
Sponsor Name: Bayer AG
Legal Registered Address:
Bayer AG, 51368 Leverkusen, German y 
Regulatory Agency Identifier Number(s):
IND: not applicable
EudraCT: 2021-003053-37 
Protocol Date: 24 JUN2021
Name: Role: Global Clinical L eader
This is an electronically  generated document that does not bear any sponsor signatures. The 
signature of the sponsor’s medically  responsible person i s filed in the TMF and available on 
request.
Medical Monitor name and contact information will be provided separately.
Confidential
The information provided in this document is strictly confidential and is inte nded solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinical investigation or its use for any other purpose w ithout the prior written co nsent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.
PPD
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 2of 25
Table of Contents
Title Page ................................................................................................................................... 1
Table of Contents ..................................................................................................................... 2
Table of Tables ......................................................................................................................... 3
1.Protocol Summar y
............................................................................................................ 4
1.1 Synopsis ........................................................................................................................... 4
1.2 Schema ............................................................................................................................. 5
1.3 Schedule of Activiti es (SoA) ........................................................................................... 5
2.
Introduction ....................................................................................................................... 6
2.1 Study  Rationale ................................................................................................................ 6
2.2 Background ...................................................................................................................... 6
2.2.1 Diabetic Kidney  Disease (DKD)
.................................................................................. 6
2.2.2
Mineralocorticoids Receptor Antagonists (MRAs) in Treatment of DKD and 
cardiovascular diseases ................................................................................................. 7
2.2.3 Role of inflammation and fibrosis ................................................................................ 7
2.3
Benefit/Risk Assessment ................................................................................................. 7
2.3.1 Risk Assessment ........................................................................................................... 8
2.3.2 Benefit Assessment ...................................................................................................... 8
2.3.3
Overall Benefit: Risk Conclusion................................................................................. 8
3.Objectives and Endpoints ................................................................................................. 9
4.Study Design ...................................................................................................................... 9
4.1 Overall Design ................................................................................................................. 9
4.2 Scientific Rationale for Study  Design ........................................................................... 10
4.3 Limitations of the Study ................................................................................................ 11
4.4 Justification for Dose ..................................................................................................... 11
4.5 End of Study  Definition ................................................................................................. 11
5.Study Population ............................................................................................................. 11
5.1 Inclusion Criteria
........................................................................................................... 11
5.2 Exclusion Criteria .......................................................................................................... 12
5.3 Lifesty le Considerations ................................................................................................ 12
5.4 Screen Failures ............................................................................................................... 12
5.5 Criteria for Temporaril y Delay ing................................................................................. 12
6.Study Intervention(s) and Concomitant Therapy ........................................................ 12
6.1 Study  Intervention(s) Administered ............................................................................... 12
6.2 Preparation/Handling/Storage/Accountability ............................................................... 12
6.3
Measures to Minimize Bias: Randomization and Blinding ........................................... 12
6.4 Study  Intervention Compliance ..................................................................................... 12
6.5 Dose Modification ......................................................................................................... 12
6.6 Treatment of Overdose .................................................................................................. 13
6.7 Concomitant Therap y
.................................................................................................... 13
7.Discont inuation of Study Intervention and Participant 
Discontinuation/Withdrawal .......................................................................................... 13
7.1 Discontinuation of Study I ntervention ........................................................................... 13
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... 13
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 3of 25
7.3 Lost to Follow Up ................................ ................................ ................................ .......... 13
8.Study Assessments and Procedures ............................................................................... 13
8.1 Efficacy  Assessments .................................................................................................... 13
8.2 Safety  Assessments ........................................................................................................ 13
8.3 Adverse Events (AEs), Serious Adverse Events (SAEs) and Other Safet y Reporting ..
13
8.4 Pharmacokinetics ........................................................................................................... 13
8.5 Genetics and/or Pharmacogenomics .............................................................................. 13
8.6 Biomarkers ..................................................................................................................... 14
8.6.1 Biomarker anal ysis..................................................................................................... 14
8.6.2 Timing of sample collection ....................................................................................... 14
8.6.3 Specimen ty pe(s) ........................................................................................................ 14
8.6.4 Sample storage ............................................................................................................ 14
8.6.5 Analy tical procedure and quality  controls .................................................................. 15
8.6.6
Data Pooling ............................................................................................................... 15
8.6.7
Reporting .................................................................................................................... 15
8.7 Immunogenicit
y Assessments ........................................................................................ 15
8.8 Health Economics or Medical Resource Utilization and Health Economics ................
15
9.Statistical Considerati ons............................................................................................... 15
9.1 Statistical Hy potheses .................................................................................................... 15
9.2 Sample Size Determination ........................................................................................... 15
9.3 Analy sis Set ................................................................................................................... 16
9.4 Statistical Analy ses........................................................................................................ 17
9.5 Interim Anal ysis............................................................................................................. 17
10.Supporti ng Documentation and Operational Considerations
.................................... 17
10.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................
17
10.1.1 Regulatory  and Ethical Considerations ...................................................................... 17
10.1.2 Financial Disclosure ................................................................................................... 18
10.1.3 Informed Consent Process .......................................................................................... 18
10.1.4 Data Protection ........................................................................................................... 18
10.1.5 Committees Structure ................................................................................................. 18
10.1.6 Dissemination of Clinical Study  Data ........................................................................ 18
10.1.7 Data Qualit y Assurance .............................................................................................. 19
10.1.8 Source Documents ...................................................................................................... 19
10.1.9 Study  and Site Start and Closure ................................................................................ 20
10.1.10 Publication Policy ....................................................................................................... 20
10.2
Appendix 2: Abbreviations ............................................................................................ 22
11.References ........................................................................................................................ 24
Table of Tables
Table 9
–1: Estimated power for the primary  endpoint ............................................................ 16
Table 9
–2: Anal ysis sets ........................................................................................................... 16
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 4of 25
1. Protocol Summary
1.1 Synopsis
Protocol Title:
A non- blinded retrospective biomarker add -on study  to FIGARO -DKD for B ioprofiling the 
pharMacody namic response to finerenone in FIGARO -DKD subjects ( FIGARO -BM)
Brief Title: FIGARO -BM
Rationale:
Alarge bod y of evidence in animals demonstrates beneficial, anti -fibrotic and anti-
inflammatory  effects of finerenone treatment. In humans, persistent inflammation and fibrosis 
are characteristic features ofchronic kidney  disease and are independent predictors of disease 
progression. Yet, there is limited data in humans to support finerenone’s mode -of-action 
(MoA) with regards to anti -fibrotic and anti- inflammatory  activity . This analy sis aims at
contribut ingto a better understanding of the underly ing mechanisms of drug efficacy  and 
pharmacod ynamics (P D) with particular focus on inflammation and fibrosis besides general 
bioprofiling and pathway anal ysis.
Objec tives and Endpoints :
Objectives Estimands/ Endpoints
Primary
To investigate long -term effect of 
finerenone treatment, in addition to 
standard -of-care, on circulating blood 
biom arkers associated with fibrosis, 
congestion, inflammation and vascular 
functionChange in plasma biomarker levels after 36 
months (Visit 11) of treatment versus 4 
months (Visit 3) of treatment in a set of 27 
pre-defined biomarkers ( provided in the 
SAP)
Overall Design :
FIGARO -BM(#21952) is a retrospective, non- interventional study to the multi- center, 
interventional Phase 3 trial FIGARO- DKD (#17530). Samples which had been collected in
FIGARO -DKD will be analy zed by  OLINK proteomics technology in FIGARO -BM.
Samples for anal ysis in FIGARO -BM will be obtained from FIGARO -DKD trial sites with 
large enrollment numbers, from subjects who had been treated with finerenone or placebo for 
at least 24 months. Certain countries require a local protocol addendum to FIGARO- DKD 
(#17530) to conduct this planned biomarker anal yses using OLINK technology, instead of a 
separate study  protocol described in this document as FIGARO -BM (#21952). B iomarker 
data acquired under FIGARO -DKD #17530 will be pooled and reported together with 
biomarker data acquired under FIGARO -BM #21952.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 5of 25
Brief Summary:
Study #21952 in subjects with DKD will examine the mid -to long-term PDresponse to 
finerenone (vs plac ebo) after up to 36 months of treatment and will characterize relevant
biological pathways which may  be affected by treatment . The focus is on markers related to 
fibrosis and inflammation due to the mode-of- action of finerenone and preclinical and clinical
evidence for finerenone and other MRAs. 
Only  existing stored biosample leftovers from FIGARO -DKD (#17530) will be used. No 
additional biological samples or data will be obtained from the subject, nor will any  additional 
or new study  intervention be introduced. N o visit or patient contact other than for obtaining 
IC will be required .
Commercially  available exploratory biomarker panels (OLINK Explore®) will be employ ed
for anal yses of the samples and all endpoints will be exploratory . OLINK Explo re®couples 
antibody -array -based analy te-capturing with next generation sequencing (NGS) for anal yte 
identification, thereb y allowing simultaneous detection of hundreds of proteins and extensive 
bioprofiling of the response to finerenone.
Number of Participants for Reconsenting:
The targeted number of participants for final anal ysis is approximately  600 (or more) 
FIGARO -DKD patients (at a 1:1 randomization for finerenone versus placebo
Intervention Groups and Duration:
No new intervention will be a dministered in this 
retrospective biomarker study .
Data Monitoring/ Other Committee:
Not applicable.
1.2 Schema
Not applicable.
1.3 Schedule of Activities (SoA)
Obtain informed consent from former stud y participants of FIGARO -DKD to 
perform further anal yses of existing biosample s(alread y collected in FIGARO -
DKD).
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 6of 25
2. Introduction
Thisprotocol describes a biomarker add-on study  to the P hase 3trial FIGARO -DKD 
(#17530). While the original trial , FIGARO- DKD, investigated the efficacy and safet y of 
finerenone (a next -generation, non-steroidal mineralocorticoid- receptor antagonist [MRA ]) on 
the reduction of cardiovascular morbidity  and mortality  in subjects with ty pe 2 diabetes 
mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care, 
this study (#21952) will solely  perform exploratory  biomarker anal yses. All analy ses will be 
done
onexisting leftover samples from selected FIGARO -DKD patients. No additional 
biological sample sor data will be collected , and no new or additional study intervention will 
be performed. The sponsor will obtain informed consent from former participants of 
FIGARO -DKD subjects to consent to this additional biomarker anal ysis on their sample 
leftovers. Biomarkers described in this protocol (analy tes)will be anal yzed bynovel 
proteomics technology (OLINK Explore®) allowing quantitative measurements of a multitude 
of markers inasmall sample volume .
2.1 Study Rationale
This study  focus eson biomarkers of inflammation and fibrosis. 
Persistent inflammation and fibrosis are characteristic features in patients with chronic  
kidney  disease 
(CKD) and are independent predictors of disease progression. While a large 
body  of evidence in animals demonstrates beneficial, anti- fibrotic a nd anti -inflammatory  
effects of finerenone treatment, there is limited data in humans to support the mode -of-action 
(MoA) with regards to anti -fibrotic and anti- inflammatory  effects. 
This analy sis may  contribute to a better understanding of the underl ying mechanisms of drug 
efficacy and pharmacodynamics ( PD)with regards to inflammat ion and fibrosis and will 
further knowledge of the biological pathway s which underpin drug efficacy  and PD. Due to 
the exploratory  nature, this biomarker study  is purely  hypothesis -generating and will 
investigate theeffect of treatment on biomarkers in the conte xt of physiolo gical and 
pathological pathway  networks.
2.2 Background
2.2.1 Diabetic Kidney Disease (DKD)
Diabetic kidney  disease ( DKD) is a clinical sy ndrome affecting individuals with diabetes. It is 
defined b y albuminuria on at least 2 occasions separated b y 3 to 6 months and eGFR of less 
than 60 mL /min/1 .73m2(1). DKD is the mo st frequent cause of end - stage renal disease 
(ESRD) in western countries (2). T he risk of cardiovascular ( CV) events and death increases 
in patients with DKD with decreasing glomerular filtration rate (GFR) and increasing 
albuminuria (3, 4). Patients with non –dialy sis -dependent chronic kidney  disease (NDD -CKD) 
are 10 times more likel y todie of CV diseases (CVD) than the general population (5).As type 
2 diabetes mellitus ( T2DM )will rise rapidly  throughout the world within the next y ears(6), 
and alongside DKD, there is an increasing need for new therapeutic agents that effectively  
target underl ying disease mechanisms and slow or halt the progression of kidney  disease, 
whilst also addressing the high CV morbidit y and mortality in this population. Interventions 
to improve outcomes related to DKD focus on reducing risk, including couns eling on lifest yle 
modifications (i.e. smoking cessation and dietary  modifications to reduce proteinuria and aid 
in weight loss) and interventions aimed at gl ycemic control, dy slipidemia, and hy pertension
(7). Therefore, angiotensin -converting -enzy me inhibitors (ACEI s) and angiotensin -receptor 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 7of 25
blockers (ARBs) are standard of care (SoC) therapy in patients with DKD and are often 
prescribed to pa tients with DKD at earl y stages (7). However, they  slow but neither halt nor 
reverse kidney  disease progression (8). 
2.2.2 Mineralocortico ids Receptor Antagonists 
(MRAs) in Treatment of 
DKD and cardiovascular diseases
Long -term renin -angiotensin sy stem (RAS ) blockade with ACEIs and ARBs results in 
incomplete suppression of serum aldosterone levels. This is known as the ‘ aldosterone 
breakthrough’ phenomenon (9). It is associated with increased urinary  albumin excretion and 
more rapid decline in estimated GFR (eGFR ). This phenomenon is probabl y due to an 
increase in potassium and angiotensin serum levels in patients treated with ACEIs /ARBs , and 
it provides the scientific rationale for an additive benefit of mineralocorticoid -receptor ( MR)
blockade.
Inappropriate release of aldosterone contributes to organ damage found in chronic renal 
failure, heart failure (HF) , myocardial infarction and hy pertension. The MR is extensively  
expressed in the CVsystem including kidney  mesangial cells, the heart, endothelial cells and 
vascular smooth muscle cells . The actual mechanisms behind the pathological effects of 
aldosterone in DKD have not y et been full y elucidated
;however, aldosterone seems to be a 
key play er in the progression of kidney  disease . Chronically  elevated aldosterone release 
participates in the g eneration of vascular, m yocardial, and renal fibrosis, and eventuall y end -
organ damage, d ysfunction, and failure (10). The actual mechanisms behind the pathological 
effects of aldosterone in DKD have not yet been fully  elucidated .Blockade of the action of 
aldosterone and potentially  other MR ligands such as cortisol has been demonstrated to be of 
benefit in different forms of CVD
(11). Steroidal MRAs currentl y on the market for the 
treatment of chronic heart failure (CHF) (spironolactone and eplerenone) have several 
disadvantages –particularly , an increased risk of hyperkalemia -which limit their use in 
clinical practice. None of the steroidal MRAs are curre ntly approved for the treatment of 
patients with CKD as they have 
a high risk of h yperkalemia (12, 13). Finerenone is a novel, 
potent, and non -steroidal MRAs with superior selectivity  vs. spironolactone in vitro and with 
improved potency  and efficacy  vs. eplerenone, which suggests an improved efficacy  and 
safet y profile and thus a potential treatment option for CKD in T2DM and HF (14).
2.2.3
Role of inflammation and fibrosis
By propagating inflammation and fibrosis, aldosterone play s a pivotal role in renal vascular 
damage. In hypertensive rat models , MRAs attenuated renal damage and supported the 
protective effect of aldosterone blockage in renal disease
(15). Other p reclinical data from 
ischem ia models of AKI1-to-
CKD progression in several species pointed towards a role of 
MRAs in polarizing macrophages to a less inflammatory  phenoty pe. Along with these 
findings, kidney  fibrosis was reduced ( 16). Finerenone was shown in animal models to act by  
targeting inflammatory  and fibrotic pathway s in the heart and kidney , reduc ingcar diac 
remodeling , and decreasing the release of inflammatory  and profibrotic biomarkers ( 17).
2.3 Benefit/Risk Assessment
This study  will o nlyinclude patients who had participate d in the FIGARO- DKD trial .
                                                
1AKI = Acute Kidney Injury
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 8of 25
2.3.1 Risk Assessment
Participati ngin this study bears no foreseeable risk to the patient . There is no intervention, no 
blood nor data collect edbeyond what wasalread y obtained during FIGARO -DKD.
2.3.2 Benefit Assessment
Patients with advanced kidney  disease show high levels of fibrosis in the kidney . Therefore, 
data to substantiate anti- fibrotic activity  of finerenone will open new treatment options for the 
patient bey ond currentl y available treatment regimens which target other aspects of kidney  
pathophy siology .
This retrospective study  offers the possibility  tobetter characterize mid-tolong-term PD 
effects offinerenone and to bioprofile the response to finerenone with particular focus on 
established aldosterone -driven, fibrosis -and inflammation -related pathway s.The results of 
this study  will be used to guide the decision on further development of finerenone by 
contributing to a better understanding of underly ing mechanisms for better outcomes in future 
useof finerenone . 
2.3.3 Overall Benefit: Risk Conclusion
The bene fit-risk assessment is considered positive and justifies the conduct of this study  
within the selected cohort of patients with CKD and T2DM .
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 9of 25
3. Objectives and Endpoints
The endpoints below all rely on data derived with an exploratory biomarker panel 
(OLINK technology) and hence, all analyses are considered exploratory in nature.
Objectives Estimands/ Endpoints
Primary
To investigate long-term effect of 
finerenone treatment, in addition to 
standard -of-care, on circulating blood 
biom arkers associated with fibrosis, 
congestion, inflammation and vascular 
functionChange in plasma biomarker levels after 36
months (Visit 11) of treatment versus 4 
months (Visit 3) of treatment in a set of 27 
pre-defined biomarkers ( provided in the 
SAP)
Other pre -specified
To characterize mid -to long -term PD 
effects of finerenone and profiling the 
response to finerenone (vs placebo) in 
patients with DKD to describe biological 
pathwaysChange in plasma biomarker levels after 12 
months (Visit 5), 24 months (Visit 8) and 36 
months (Visit 11) , 48 months (Visit 14)2of 
treatment versus 4 months (Visit 3) of 
treatment
To further investigate the study intervention 
and similar drugs (e.g. mode -of-action -
related effects, safety ) and to further 
investigate pathomechanisms deemed 
relevant to renal and cardiovascular 
diseases and associated health problemsChange in various biomarkers (e.g. 
diagnostic, safety, pharmacodynamic, 
monitoring, prognostic or potentially 
predictive biomarkers)
To assess relationship between 
pharmacokinetics of finerenone and PD
effectsChange in biomarker levels at 12 months
(Visit 5), 2 4 months (Visit 8) and 3 6 months
(Visit 11) of treatment compared to exposure
4. Study Design
4.1 Overall Design
FIGARO -BM(#21952) is aretrospective, non- interventional add-on study to the multi- center , 
interventional Phase 3 trial FIGARO -DKD (#17530). Blood 
plasma samples which were 
initially  collected for pharmacokinetic (PK) analysis during the conduct of FIGARO -DKD 
study  will be anal yzed by OLINK pr oteomics technology  (refer to 
Section 8.6for details on 
biomarkers and intended technology )in FIGARO -BM.
This biomarker study willcontact selec tedsubjects from multiple centers in several countries
who had participated inFIGARO -DKD and subjects will be re-consent edforfurther 
biomarker analyses.Sites with a large number of subjects in FIGARO -DKD –preferentiall y
with ~
8 or more valid3subjects per site who were on treatment with finerenone (or placebo) 
                                                
2Depending on availability of samples for visit
3Valid Subjects does not include subjects with known fatal outcome and/or subjects which otherwise do not 
meet enrolment criteria . Subject s with very high baseline risk (eGFR ≤25mL/min/1.73m2 ) or low  baseline risk 
(normal albuminuria and eGFR ≥60mL/min/1.73m2 ) will be excluded because the treatment effect on 
biomarkers is less likely to be observed in these subjects and w ould need a higher number of subjects per arm 
(see Section 9.2).
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 10of 25
for at least 24months -will be selected in order to investigate mid -to long -term treatment 
effects of finerenone in a cross- section of subjects from FIGARO -DKD .Countries will be 
selected based on above- average recruitment in FIGARO -DKD, short anticipated turn- around 
time to f
irst patient first consent ,and a sufficient number of sites and potentially  available 
subjects interest edin partic ipation in this study .
Certain countries r equire a local protocol addendum to the parent study  FIGARO -DKD 
#17530 to conduct this planned biomarker analy ses using OLINK technology , instead of a 
separate study  protocol described in this document as FIGARO -BM (#21952). Biomarker 
data acquired under FIGARO -DKD will be pooled and reported together with biomarker data 
acquired under FIGARO -BM.
The pooled data isintended to include approximately  600 (or more) FIGARO -DKD patients
from 60 (or more) sites.
4.2 Scientific Rationale for Study Design
The o verall rationale is described in detail in Section 2.1.
This study  uses exploratory , commercially  available biomarker panels ( OLINK Explore®). 
Hence all endpoint sarealso exploratory  in nature. 
OLINK Explore®is a novel technology  
which uses proteomics coupled to NGS4-detection methodologies (18).This is a very  recent 
technology , which allows extensive bioprofiling of the PDresponse to finerenone. At the time 
FIGARO -DKD was set up, these techno logies were not available. Since the introduction of 
OLINK Explore®to the market in mid -2020 only  few groups have conducted similar anal yses 
(e.g. (18-20 ) ). The biomarker studies -which were carried out in ARTS (#14563 (22)and 
later, as sub
-studies to FIGARO -DKD (#17530, report in preparation), FIDELIO -DKD 
(#16244 (21)) or) -suggest potential antifibrotic activity  and warrant further investigation of 
circulat ingfibrosis markers. 
The primary  endpoint of FIGARO -BMfocuses on fi brosis and inflammatory  markers which 
have been reported in literature in the context of CVDs (see for example: ( 19)).FIGARO -BM
will investigate first and foremost whether finerenone treatment (compared to placebo) affect s
markers of fibrosis and inflammation after mid-to long-term treatment. Impacting circulating 
levels of fibrosis -
related biomarkers is generall yassumed to be of long -term benefit to 
patients with 
CKD as kidney  fibrosis is the common endpoint of C KDfrom various etiologies
(16).Therefore, modulating fibrosis markers may reflect treatment efficacy and hence may  
translate into a clinicall y relevant benefit to the patient .
Taken together ,multiple lines of evidence support that finerenone acts via inflammatory  and 
fibrosis -related pathway s. Yet, human data on fibrosis biomarker panels from randomized 
clinical trials ( RCTs )with finerenone is missing to this point .While an individ ual biomarker 
of fibrosis or inflammation may  not be informative to understand the intricate network of
pathologic (or phy siologic) proce sses and apotential interaction with the intervention , a 
network anal ysisof a large number of biomarkers may provide insights into linkages of 
                                                
4Next generation sequencing (NGS) is used as a detection method in order to identify specific protein labels. 
There is no genetic information assessed, collected or analyzed. The current commercial version of this OLINK 
biomarker panel in cludes 1536 biomarkers but is expected to be extended to 3000 markers or more by the end of 
the year 2021.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 11of 25
pathway s and how or if they  are affected by  treatment. In addition, biomarkers will be 
assessed longitudinally . Hence, t his bioprofiling approach allows to analyzephysiologicall y 
linked biomarkers over time which may more convincingl y demonstrate remodeling events 
along the time axisthan individual markers alo ne -without consideration of their context and 
time trajectory .
4.3 Limitations of the Study
Since PK blood samples were not collected at baseline in the main study , no changes from 
baseline will be anal yzed. Hence, the focus of this study  will beon mid -(i.e. ≥12 months of 
treatment) to long -term biomarker changes. Given that 
organ remodeling is a slow process 
over months to y ears, this limitation is considered acceptable. In addition, the study  is a 
retrospective anal ysis of biomarkers from selected patients ,sites and countries. I t is likel y that 
the focus on larger sites will lead to selection bias. In addition, patients with fatal outcome are 
no longer available f or consenting, excluding risk 
analyses with regards to death. Yet, the 
emphasis is on understanding biological pathway s and better describe the mode -of-action of 
finerenone in humans.
4.4 Justification for Dose
Not applicable.
4.5 End of Study Definition
The end of the stud y is defined as the date when the last subject provides consent into the 
study  globally .
5. Study Population
This study  will only  include p atients who were enrolled in the FIGARO- DKD study (see CSP 
FIGARO -DKD stud y#17530 ) and had received up to 20 mgfinerenon e or placebo for
≥24months.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Signed informed consent to participate in FIGARO -BM5
Randomi zed in the FIGARO -DKD trial
For eac h participant, PK plasma sample sfrom Visit 3 andat least 2 other Visits 
(Visit 5, Visit 8, Visit 11) must be available on storage from the main study
FIGARO -DKD.6,7
                                                
5Capable of giving signed informed consent as describ ed in Section 10.1.3 which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
6Participants w ith a complete set of PK blood samples up unti l 36 months of treatment (Visit 3, Visit 5, Visit 8, 
Visit 11) should be prioritized by sites over those which have incomplete sets of PK samples. 
7Note that some subjects may have additional and/or unscheduled visits (PK samplings) which may be analyzed .
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 12of 25
5.2 Exclusion Criteria 
Subjects which did not show overall compliance of 80 to 120% with study 
intervention in FIGARO -DKD 
Subjects which were not part of the full analy sis set (FAS) of FIGARO- DKD .
Subjects with known fatal outcome 
Subjects with baseline eGFR ≤25 mL /min/1.73m2
Subjects with l ow baseline risk (normal albuminuria and 
eGFR ≥
60mL/min/1.73m2 )
Sponsor request (after discussion with the investigator), for reasons such as a 
significant protocol deviation
5.3 Lifestyle Considerations
Notapplicable. 
5.4 Screen Failures
Not applicable .
5.5 Criteria for Temporarily Delaying
Not applicable.
6. Study Intervention(s) and Concomitant Therapy
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a stud y participant according to 
the study  protocol.
6.1 Study Intervention(s) Administered
None.
6.2 Preparation/Handling/Storage/Accountability
Not applicable.
6.3 Measures to Minimize Bias: Randomization and Blinding
Not applicable.
6.4 Study Intervention Compliance
Not appl icable. 
6.5 Dose Modification
Not applicable.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 13of 25
6.6 Treatment of Overdose
Not applicable.
6.7 Concomitant Therapy
Not applicable. 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal 
7.1 Discontinuation of Study Intervention 
Not applicable.
7.2 Participant Discontinuation/Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request
If the participant withdraws consent, the sponsor may  retain and continue to use 
any data collected before such a withdrawal of consent.
7.3 Lost to Follow Up
Not applicable.
8. Study Assessments and Procedures
Protocol waivers or exemptions are not allowed. There are no stud y specific procedures for 
this biomarker study  except for requesting the re -consent for use of existing samples. For 
details on biomarkers and sample anal ysis,refer to Section 8.6.
8.1 Efficacy Assessments 
Not applicable .
8.2 Safety Assessments
Not applicable. There will be no study -specific safety  assessments in this study . Safet y of the 
participants was monitored within the 
FIGARO -DKD stud y.
8.3 Adverse Events (AEs) ,Serious Adverse Events (SAEs) and Other Safety 
Reporting
Not applicable.
8.4 Pharmacokinetics
Not applicable.
8.5 Genetics and/or Pharmacogenomics
Not applicable .
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 14of 25
8.6 Biomarkers
8.6.1 Biomarker analysis
This study  will anal yze only blood -based biomarkers. Genetic biomarkers will not be 
measured.
The primary  anal yses will be carried out using the OLINK Explore®assay . The current 
version of the OLINK Explore®will provide biomarker data for 1536 biomarkers including 
hundreds of 
CVand inflammatory  biomarkers8. “Biomarkers of primary interest ” are 
summarized in the statistical anal ysis plan (SAP) and constitute the primary  study  endpoint . 
The full list of all biomarkers anal yzed will be given in the study  report. 
The list of “biomarkers of primary  interest” consists primarily  of biomarkers of inflammation 
and fibrosis which have been published previously  in the cont ext of inflammation- related 
fibrosis and CKD. The list includes e.g. metallomatrix protein -2 (also known as CCL 2), C -C 
motif chemokine 16 (CXCL 16), connective tissue g rowth factor (CTGF, also known as CCN 
family  member 2) ,or N-terminal pro -brain natriuret ic peptide (NT -proBNP9). 
Confirmatory analyses , e.g. to confirm biomarkers results from the primary anal yses by 
using alternative methodologies - such as e.g. research- use immunoassay s, routine clinical 
chemistry  or immunoassay  platforms (e.g. Roche Cobas , Abbott Architect, Siemens Centaur), 
high performance liquid chromatograph y (HPL C)or mass spectrometry , may  be carried out.
Further biomarkers related to the mode of action or the safet yoffinerenone andsimilar 
drugs may  be examined. The same applies to further biomarkers deemed relevant to renal and 
cardiovascular diseases and associated health problems. These investigations may include e.g. 
diagnostic, safet y, PD, monitoring, or potentiall y predictive biomarkers.
8.6.2 Timing of sample collection
Not applicable10.
8.6.3 Specimen type (s)
Leftover samples, originally  collected for PKanaly sis (lithium heparin plasma) in FIGARO -
DKD (#17530) ,will be used for this biomarker study . For d etails on sample collection 
refer to
the study  documentation of FIGARO -DKD (#17530 - e.g. sample handling sheets or lab 
manual).
8.6.4 Sample storage
Samples may  be stored for a maximum of 15 y ears (or according to local regulations) 
following finalization of the study  report for this study at afacilit y selected by the sponsor to 
enable further anal yses.
                                                
8This panel is subject to regular adaptations by the manufacturer to consider newly identified biomarkers. For 
this study, the latest available OLINK Explore Panel w ill be used. The composition of OLINK Explore®along 
with the UniProtID and gene names f or each biomarker is published on www.olink.com . The complete protein 
list for the current Explore® can be found here: https://www.olink.com/content/uploads/2021/03/explore -1536 -
assay -list-20210227 -web.xlsx (as of 31 May 2021 -Note: This link is not automatically updated.)
9NT-proBNP has also been analyzed in two other substudies of FIGARO -DKD using different analytical 
methodologies. Results for these substudies have been or, for still ongoing analyses under protocol #17530, 
will be reported under separated cover.
10There will be no new sample collection in the course of this biomarker study. 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 15of 25
8.6.5 Analytical procedure and quality controls
Details of the analy tical procedures and quality  controls (if applicable) will be provided b y the 
analyticallaboratory (e.g. validation/analy tical repo rt)at the end of the study.
8.6.6 Data Pooling
Biomarker data acquired under FIGARO-DKD #17530 will be pooled and reported together 
with biomarker data acquired under FIGARO- BM #21952 (see also Section 4.1).
8.6.7
Reporting
Biomarker investigations as described herein (see Section 3) as “ P rimary ” (see Section 3 or 
within the SAP)will be reported inaclinical study  report. Other exploratory  anal ysesmay be 
reported separatel y (e.g. in a biomarker evaluation report) .
8.7 Immunogenicity Assessments
Not applicable .
8.8 Health Economics orMedical Resource Utilization and Health 
Economics
Not applicable.
9. Statistical Considerations 
9.1 Statistical Hypotheses
All analy ses for this study  are exploratory . 
The primary objective (Section 3) is to analy ze the c hange in plasma biomarker levels after 
36 months (Visit 11) of treatment versus 4 months (Visit 3) of treatment in a set of 27 pre-
defined biomarkers (provided in the SAP )in treatment group compared to placebo , based on 
the 
biomarker full analysis set (BFAS )as defined in Section 9.3. A two- sided moderated t -
tests(23)between treatment and placebo group on the log -transformed ratios of biomarker 
levels from Visit 11 to Visit 3, based on the complete OLINK panel , will be used in the 
analysis. This anal ysis will be adjusted for relevant baseline covariates. P -values of the 27 
biomarkers of primary  interest will be adjusted for multiple testing according to Benjamini 
and H ochberg (24).A biomarker is considered to be affected b y treatment, if the adjusted p -
value is less or equal to 5%.
Summary  statistics and line plots (mean with geometric standard deviation [ gsd]
-or standard 
deviation [ sd] error bars over time) for the ratio to Visit 3 will be generated.
The remaining biomarkers will be analy zed according to SAP or under separate cover. Refer 
to SAP for further d etails.   
9.2 Sample Size Determination 
Table 9–1 summarizes the results of a power simulation based on the following assumptions :
Beneficial effect of finerenone on 4of the 27 biomarkers with a ratio of biomarker 
levels from Visit 11 to Vis it 3 (month 4) under finerenone of 10% , 15% or 20%
compared to placebo.
Inter -subject variability  of 25% (geometric standard deviation of 1.25)
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 16of 25
Intra -subject variability  from Visit 3 to Visit 11 of 20% (gsdof 1.2)
Assay -variability  of 10% (gsdof 1.1)
Table 9–1: Estimated power for the primary endpoint
Treatment 
effect sizeNumber of 
subjects per 
armPower to detect 
4 biomarkersPower to detect 
3 biomarkers or 
morePower to detect 
2 biomarkers or 
morePower to detect 
1 biomarkers or 
more
10% 75 2.5% 5.4% 9.5% 16.8%
100 4.5% 9.2% 15.2% 24.2%
250 26.4% 42.0% 55.2% 67.4%
300 37.4% 55.4% 66.9% 77.4%
400 57.6% 74.4% 83.6% 90.3%
15% 75 13.4% 24.3% 34.9% 48.0%
100 24.2% 39.3% 51.8% 63.8%
250 86.1% 94.8% 97.7% 99.2%
300 94.2% 98.8% 99.5% 99.9%
400 99.4% 100.0% 100.0% 100.0%
20% 75 45.0% 62.4% 74.0% 83.4%
100 67.3% 82.0% 89.5% 94.3%
250 99.9% 100.0% 100.0% 100.0%
300 100.0% 100.0% 100.0% 100.0%
400 100.0% 100.0% 100.0% 100.0%
Power estimations are based on the methodology described in Section 9.4and Monte -Carlo 
simulations with 10,000 iterations per scenario. Numbers in bold indicate the anticipated number 
of subjects per arm (total subjects = 600). Gre yshading indicates a power of ≥80%
As shown in Table 9–1, the intended patient number of 600 with 300 subjects per arm 
(finerenone and placebo 1:1) would lead to a power of 94.2% to correctly  detect all 4 
biomarkers with beneficial effect at an esti mated effect size of 15% between visit 3 (4 
months) and visit 11 (36 months).
For description of the panels refer to Section 8.6.All simulations concerning sample size 
determination were conducted using R.
9.3 Analys i
s Set
Analy sis sets are defined in Table 9–2:
Table 9
–2: Analysis sets
Participant A nalysis Set Description
BFAS (Biomarker Full 
Analy sis Set)All participants with valid informed consent for this 
biomarker stud y and which meet study  enrollment
criteria as defined in Section 5.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 17of 25
9.4 Statistical Analyses
Selected demographics and disposition tables from FIGARO- DKD will be repeated for the 
biomarker subset. For details refer to the corresponding SAP.
For a detailed analy sis plan and further exploratory  analy ses refer to SAP.
9.5 Interim Analys is
There will be noformal interim anal ysis. The study is unblinded.
10. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Co nsiderations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the 
following:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents ( e
.g.,advertisements) must be submitted to an IRB/IEC by  the 
investigator and reviewed and approved b y the IRB/IEC before the stud y is 
initiated. 
Any amendments to the protocol will require IRB/I EC approval before 
implementation of changes made to the stud y design, except for changes necessary 
to eliminate an immediate hazard to study  participants. Any substantial 
modification of the protocol will b e submitted to the competent authorities as 
substanti al amendments for approval, in a ccordance with I CH Good Clinical 
Practice and national and international regulations.
Protocols and an y substantial amendments to the protocol will require health 
authorit y approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants .
The investigator will be responsible for the following:
Providing written summaries of the status of the study
 to the IRB/IEC 
annually  or mo re frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/IEC
Notify ing the IRB/IEC of SAEs or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of ICH guidelines, the I RB/IEC, and all other applicable local 
regulations
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 18of 25
10.1.2 Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant sor their legally  authorized representative and answer all questions 
regarding the stu dy. 
Participants must be informed that their participation is voluntary . Participants will 
be required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, I CH guidelines, Health I nsurance Portabilit y and 
Accountability  Act (HI PAA) requirements, where applicable, and the IRB/IEC or 
study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to th e participant s. 
10.1.4 Data Protection
Participants will be assigned the same unique identifier by  the sponsor as in the 
FIGARO -DKD stud y. Any  participant records, datasets or biological samples that 
are transferred to the sponsor will contain the identifier onl y; participant names or 
any information which would make the participant identifiable will not be 
transferred.
The participant must be informed that his/her personal study -related data will be 
used by  the sponsor in accordance with local data protection la w. The level of 
disclosure must also be explained to the participant who will be required to give 
consent for their data to be used as described in the informed consent
The participant must be informed that his/her medical records may  be examined by  
Clini
cal Quality  Assurance auditors or other authorized personnel appointed by  the 
sponsor, by  appropriate IRB/IEC members, and by  inspectors from regulatory  
authorities.
10.1.5 Committees Structure
Due to the non- interventional nature , no committee structure has been established for this 
retrospective biomarker study . No additional subject data will be collected in this study .
10.1.6 Dissemination of Clinical Study Data
Results of clinical drug trials will be provided on EU Clinical Trials Re gister in line with the 
applicable laws and regulations. Result summaries of Bayer's sponsored clinical trials in drug 
development Phases 2, 3 and 4 and Phase 1studies in patients are provided in the Bay er Trial 
Finder application after marketing authoriza tion approval in line with the position of the 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 19of 25
global pharmaceutical industry  associations laid down in the "Joint Position on the Disclosure 
of Clinical Trial Information via Clinical Trial Registries and Databases".
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical trials 
in patients for medicines and indications approved in the United States and European Union 
on or after 01 JAN 2014 as necessary  for conducting legitimate research.
All Bay er-sponsored clinical trials are considered for publication in the scientific literature 
irrespective of whether the results of the clinical trials ar e positive or negative.
10.1.7 Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., laboratory  
data, biomarker data ). The investigator 
is responsible for verify ing that data entries 
are accurate and correct.
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
Monitoring detai ls describing strategy  (e.g., risk- based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling 
of noncompliance issues a
nd monitoring techniques (central, remote, or on- site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
The sponsor assumes accountability  for actions delegated to other individuals (e.g.,
Contract Research Organizations).
Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by
 the investigator for 15years after study  completion 
unless local regulations or institutional policies require a longer retention period. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or part y 
without written notific ation to the sponsor. 
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported in the CRF that are tr anscribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, 
depending on the study . Also, current medical records mu st be available.
Definition of what constitutes source data can be found in theSource Data 
Location L ist (SDLL) or equivalent .
The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 20of 25
Study  mon itors will perform ongoing source data review to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of participants are 
being protected; and that the study  is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
No source data verification will be performed
10.1.9 Study an d Site Start and Closure
First Act of Recruitment
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the first patient first consent . 
Study/Site Termination
The sponsor or designee reserves the right to close the study  site or terminate the study  at any 
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been collected and a study -site closure visit has been pe rformed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator ma y include but are 
not limited to:
For stud y termination:
Discontinuation of further study  intervention development
For site termination:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate or no recruitment (evaluated after a reas onable amount of time) of 
participants b y the investigator
Total number of participants included earlier than expected.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly  inform the 
investigators , the IECs/IRBs, the regulatory authorities, and an y contract research 
organization(s) used in the study  of the reason for termination or suspension, as specified b y 
the applicable regulatory  requirements. The investigator shall promptly  inform the participant
and should assure appropriate participant therapy  and/or follow -up.
10.1.10 Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments. 
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 21of 25
support publication of multicenter studies only  in their entir ety and not as 
individual site data. I n this case, a coordinating investigator will be designated by  
mutual agreement.
Authorship will be determined by  mutual agreement and in line with I nternational 
Committee of Medical Journal Editors authorship requirements.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 22of 25
10.2 Appendix 2: Abbreviations
ACEI(s) angiotensin- converting -enzy me inhibitor(s)
AKI acute kidney  injury
ARB(s) angiotensin-receptor blocker(s)
BFAS biomarker full analysis set
BM biomarker
CCL2 metallomatrix protein -2
CHF chronic heart failure
CKD chronic kidney  disease
CRF case report form
CSP clinical study  protocol
CTGF connective tissue growth factor
CV cardiovascular
CVD cardiovascular disease
CXCL 16 C-C motif chemokine 16
DKD diabetic kidney  disease
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
GCP good clinical practice
GFR glomerular filtration rate
gsd geometric standard deviation
HF heart failure
HPL C high performance liquid chromatograph y
IC informed consent
ICF informed consent form
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 23of 25
IEC Independent Ethics Committee
IRB Institutional Review Board
MoA mode -of-action
MR mineralocorticoid -receptor
MRA mineralocorticoid -receptor antagonist
NDD- CKD non–dialy sis-dependent chronic kidney  
disease
NGS next generation sequencing
NT-proBNP N-terminal pro -brain natriuretic peptide
PD pharmacod ynamics
PK pharmacokinetics
RAS renin -angiotensin s ystem
RCTs randomized clinical trials
SAE Serious adverse event
SAP statistical analy sis plan
sd standard deviation
SoC standard of care
T2DM type 2 diabetes mellitus
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 24of 25
11. References
1. Shlipak M. Diabetic nephropathy : preventing progression. BMJ clinical evidence. 
2010;2010.
2. Fernandez Fernandez B, Elewa U, Sanchez -Nino MD, Rojas- Rivera JE, Martin -Cleary  
C, Egido J, et al. 2012 update on diabetic kidney  disease: the expanding spectrum, novel 
pathogenic insights and recent clinical trials. Minerva medica. 2012;103(4):219 -34.
3. Kidney  Disease Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical 
Practice Guideline for the Ev aluation and Management of Chronic Kidney  Disease. Kidney  
Int Suppl. 2013;3(1):1 -150.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey  AS, de Jong PE, et 
al. Association of estimated glomerular filtration rate and albuminuria with all -cause and 
cardiovascular mortalit y in general population cohorts: a collaborative meta- analysis. Lancet. 
2010;375(9731):2073
-81.
5. Gregg L Parker HS. Management of Traditional Cardiovascular Risk Fatorisin CKD: 
What Are the Data? Am J Kidney  Dis. 2018;72(5):728 -44.
6. IDF. International Diabetes Federation,Diabetes Atlas, 6th edition. online version 
wwwidforg/diabetesatlas. 2013.
7. Molitch ME, Adler AI, Fly vbjerg A, Nelson RG, So WY, Wanner C, et al. Diabetic 
kidney  disease: a clinical update from Kidney  Disease: Improving Global Outcomes. Kidney  
international. 2015;87(1):20 -
30.
8. Diseases NIoDaDaK. Kidney  Disease of Diabetes. 2014.
9. Staessen J, Lijnen P, Fagard R, Verschueren L J, Amery  A. Rise in plasma 
concentration of aldosterone during long- term angiotensin II suppression. The Journal of 
endocrinology . 1981;91(3):457-65.
10. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and 
mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 
2015;65(2):257 -63.
11. Pitt B, Zannad F, Remme WJ, Cody  R, Castaigne A, Perez A, et al. The effect of 
spironolactone on morbidity  and mortalit
y in patients with severe heart failure. Randomized 
Aldactone Evaluation Study  Investigators. The New England journal of medicine. 
1999;341(10):709 - 17.
12. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for 
preventing the progression of chronic kidney  disease. The Cochrane database of s ystematic 
reviews. 2014(4):CD007004.
13. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with 
chronic heart failure. Vascular health and risk management. 2011;7:353 -63.
14. Bayer AG. Finerenone clinical investigator brochure Version 7.0. 2020 06 Mar 2020.
15. Blasi ER, Rocha R, Rudolph AE, Blom me EA, Polly  ML, McMahon EG. 
Aldosterone/salt induces renal inflammation and fibrosis in hy pertensive rats. Kidney  
international. 2003;63(5):1791-800.
16. Barrera -Chimal J, Estrela GR, L echner SM, Giraud S, El Moghrabi S, Kaaki S, et al. 
The my eloid minera locorticoid receptor controls inflammatory  and fibrotic responses after 
renal injury  via macrophage interleukin- 4 receptor signaling. Kidney  international. 
2018;93(6):1344 -55.
17. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Steroidal and Novel 
Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal 
Diseases: Comparison at Bench and Bedside. Handb Exp Pharmacol. 2017;243:271 -305.
CONFIDENTIAL Clinical Study  Protocol
Finerenone (BAY 94 -8862) / 21952
24JUN 2021 Page: 25of 25
18. Zhong W, Edfors F, Gummesson A, Bergstrom G, Fagerberg L, Uhlen M. Next 
genera tion plasma proteome profiling to monitor health and disease. Nat Commun. 
2021;12(1):2493.
19. Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, et al. Proteomic 
and Mechanistic Anal ysis of Spironolactone in Patients at Risk for HF. JACC H eart failure. 
2021;9(4):268 -77.
20. Filbin MR, Mehta A, Schneider AM, Kay s KR, Guess JR, Gentili M, et al. 
Longitudinal proteomic analysis of severe COVID -19 reveals survival -associated signatures, 
tissue -specific cell death, and cell -cell interactions. Ce ll Rep Med. 2021;2(5):100287.
21. PH-41813. Study  16244: Association anal yses of biomarkers and echocardiographic 
parameters in the finerenone phase
III FIDELIO study . Bay er AG, D -51368 Leverkusen, German y 30 MAR 2021.
22. A52945. Study  14563: A randomized , double -blind, multi -center study  to assess 
safet y and tolerability of different oral doses of BAY 94 -8862 in subjects with stable chronic 
heart failure with left ventricular s ystolic dy sfunction and mild (Part A) or moderate (Part B) 
chronic kidney  disea se versus placebo (Part A) or versus placebo and spironolactone (Part B). 
Bayer AG, D -51368 Leverkusen, German y 26 MAR 2013.
23. Smyth GK. Linear models and empirical bay es methods for assessing differential 
expression in microarray  experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
24. Y. BYH. Controlling the false discovery  rate: a practical and powerful approach to 
multiple testing. Journal of the Roy al Statistical Society  Series B. 1995;57:289-300.